Business Segments · G&A

Reportable Segment — G&A

Amgen Reportable Segment — G&A increased by 12.5% to $623.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 22.6%, from $508.00M to $623.00M.

Analysis

StatementSegment
First reportedQ1 2024
Last reportedQ3 2025
Rolls up toG&A
Metric ID: amgn_segment_reportable_segment_general_and_administrative

Historical Data

6 periods
 Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$604.00M$574.00M$508.00M$621.00M$554.00M$623.00M
QoQ Change—-5.0%-11.5%+22.2%-10.8%+12.5%
YoY Change———+2.8%-3.5%+22.6%
Range$508.00M – $623.00M
CAGR+2.5%
Avg YoY Growth+7.3%
Median YoY Growth+2.8%

Frequently Asked Questions

What is Amgen's reportable segment — g&a?
Amgen (AMGN) reported reportable segment — g&a of $623.00M in Q3 2025.
How has Amgen's reportable segment — g&a changed year-over-year?
Amgen's reportable segment — g&a increased by 22.6% year-over-year, from $508.00M to $623.00M.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.